Biosimilars in Brazil: developments in 2015 and business perspectives

Brazil is looking into foreign technology to foster innovation in the country’s industrial health complex. Biological plants are being built and partnerships with multinationals have been established with the goal to in license technology, manufacture and supply the population with biosimilars made in Brazil. This article brings up-to-date information on the biosimilar market in the country, with information on the public-private partnerships and regulatory approvals. With two biosimilars approved in 2015 and the ongoing development regarding the local pharmaceutical companies, there is a good window of opportunity to create new businesses in the soon to be 4th pharmaceutical spender in the world.

Transformacja i globalna ekspansja brazylijskiego przemysłu lotniczego na przełomie XX i XXI wieku na przykładzie koncernu EMBRAER

The aim of the study is to analyse the process of historical growth, transformation and global expansion of the largest Brazilian aircraft industry enterprise – Embraer (Empresa Brasileira de Aeronautica). The company history can be divided into three main stages. The first one lasted from 1969 until the second half of the 1980s. In that stage, the company developed production supported mainly by the government or on license technology. The second stage lasted from the end of the 1980s to the mid-1990s. This was the stage of the crisis and transformation of the company, which ended up with its privatization and recovery. The last stage, lasting from 1996 to 2009, was characterized by dynamic growth of production and sales. The new family of regional jets (ERJ-145 and Embraer 170/190) turned out to be a great selling success which has enabled the company to maintain its position as a global leader in regional jets, which vies with the Canadian Bombardier for the third place in the world ranking of aircraft manufacturers.